Celgene terminates MAILSAIL trial for lack of effectiveness


According to a media release issued by Celgene yesterday, the company has terminated the so-called MAINSAIL trial in the treatment of men with castration-resistant prostate cancer (CRPC).

The MAINSAIL trial was a multi-center, randomized, double-blind, placebo-controlled study designed to compare docetaxel + prednisone + lenalidomide (Revlimid) to docetaxel + prednisone + placebo in men with CRPC. It had enrolled more than 1,000 patients.

The company’s media release states that:

A review by a data monitoring committee suggested that the triple-combination therapy would not demonstrate a statistically significant treatment effect against the primary endpoint of overall survival versus standard therapy.

Clearly it is disappointing to see a major drug that has proven efficacy in the management of other forms of cancer fail in the management of advanced forms of prostate cancer.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: